Don’t let the high cost of brand specialty lupus biologic therapy disrupt your treatment. We help eligible patients access Benlysta (belimumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Benlysta Prescription Assistance Program is a manufacturer-sponsored initiative that provides Benlysta at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for systemic lupus erythematosus and lupus nephritis patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, rheumatology coordination, prior-authorization documentation, infusion or specialty-pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion or refill coordination and annual re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$4,300 | Save ~$4,230/mo |
| CVS Pharmacy | ~$4,500 | Save ~$4,430/mo |
| Walmart | ~$3,700 | Save ~$3,630/mo |
| Costco | ~$3,600 | Save ~$3,530/mo |
| Specialty Pharmacy | ~$3,800 | Save ~$3,730/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Benlysta at no medication cost if approved. Our $69.95/month service covers full advocacy.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Benlysta:
Still $3,500–$4,500 per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Benlysta assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Benlysta (belimumab) is a biologic medicine — a monoclonal antibody — used to treat systemic lupus erythematosus (SLE) and lupus nephritis. It is given as either IV every 4 weeks or as a self-administered SC injection once weekly.
How Benlysta Works:
Belimumab is a monoclonal antibody designed to bind to a soluble cytokine known as B-lymphocyte stimulator (BLyS), which is overproduced in patients with lupus. By preventing BLyS from reaching its receptors, the drug reduces B-cell survival and the production of autoantibodies that cause organ inflammation. This targeted action leads to fewer disease flares, improved kidney outcomes in lupus nephritis, and a reduced need for corticosteroids.
Form and use:
Marketed as Benlysta, the medication is available as both an intravenous (IV) infusion and a subcutaneous (SC) injection. The IV version is administered at 10 mg/kg every two weeks for three doses, then every four weeks, while the SC version is a 200 mg weekly self-injection. Both forms are approved for SLE and lupus nephritis and are typically used as add-on therapies alongside standard treatments.
Generic availability:
As of 2026, there is no biosimilar version of Benlysta available in the United States. Patients may use other treatments such as hydroxychloroquine, corticosteroids, or immunosuppressants like mycophenolate and azathioprine, which have generic options. Other specialized biologics, including anifrolumab and voclosporin, are also available, while rituximab biosimilars are occasionally used off-label.
Warnings:
Benlysta carries warnings regarding serious infections, including bacterial, viral, and fungal types, as well as Progressive Multifocal Leukoencephalopathy (PML). It is associated with risks of depression and suicidality, requiring close monitoring of psychiatric symptoms. Additionally, patients should be aware of potential hypersensitivity reactions, risks of malignancy, and the contraindication of receiving live vaccines during treatment.
Benlysta costs approximately $3,500–$4,500 per IV infusion (every 4 weeks after loading) or per month of SC injections. Annual costs commonly reach $45,000–$55,000+. Through AffordMyPrescriptions, qualifying patients receive Benlysta at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Both forms have similar effectiveness. IV requires going to an infusion center every 4 weeks (after loading); SC is self-injected at home weekly. SC is more convenient for many patients; IV may be preferred if home injections are difficult or if combining with other infusions. Discuss with your rheumatologist.
Benlysta often takes time to show full effect — initial improvement may begin within 2–4 weeks, but maximum benefit (in clinical trials) is typically seen at 24 weeks or later. Don’t stop Benlysta if you don’t notice immediate improvement; continue under your rheumatologist’s guidance and reassess at planned intervals.
Discuss family planning with your rheumatologist. Belimumab crosses the placenta, especially in the second and third trimesters. Limited human data exist. Hydroxychloroquine and azathioprine are generally considered safer in pregnancy. If pregnancy is being planned, your rheumatologist will help adjust your lupus regimen accordingly.
Inactivated vaccines (annual influenza, pneumococcal, COVID-19, Tdap, HPV) are generally fine and recommended. Live vaccines (MMR, varicella, MMRV, intranasal flu, yellow fever) should be avoided while on Benlysta — they can cause active infection in immunocompromised patients. Get any needed live vaccines before starting Benlysta.
Yes. Medicare Part D (for SC) or Medicare Part B (for provider-administered IV infusions) beneficiaries can typically qualify, especially if you face specialty-tier copays you cannot afford.
If denied, we explore alternatives — switching to anifrolumab (Saphnelo) for SLE or voclosporin (Lupkynis) for lupus nephritis, optimizing standard therapy with hydroxychloroquine and immunosuppressants, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Lupus Foundation of America, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
If you are struggling with the high cost of Benlysta, our team may be able to help you access assistance programs designed to make brand specialty lupus biologics affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.